ArticleJACC. Case reports2025
TACE With Doxorubicin-Induced Cardiotoxicity.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Safety and Treatment Efficacy of Systemic, Locoregional, and Nanoparticle Encapsulated Anthracycline Chemotherapy: Insights Into Cardiotoxicity.Arteriosclerosis, thrombosis, and vascular biology · 2026Review
- Case Report: Adebrelimab-associated suspected immune-related myocarditis with myositis/myasthenia gravis overlap syndrome (IM3OS): A rapidly fatal case and clinical implications.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Doxorubicin is an effective chemotherapeutic drug used in transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma. Although very effective, this molecule is known for its potential severe cardiotoxicity, which was the purpose for the development of drug-eluting beads-TACE that showed similar efficacy and improved safety. We present the case of a 58-year-old man with hepatocellular carcinoma who received 5 treatments of conventional TACE with doxorubicin and developed severe cardiotoxicity. Although the cardiotoxic effect of TACE with doxorubicin has already been reported in the literature, this case has serious implications, because the patient had to be removed from the liver transplant waitlist and this development could have been prevented. We believe that this complication of TACE should be more known, and hence more sought out. We also believe that drug-eluting beads-TACE should be preferred because it was proven safer in more frail patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.